Carla J Treloar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6333809/publications.pdf

Version: 2024-02-01

234 papers 5,861 citations

71061 41 h-index 59 g-index

240 all docs

240 docs citations

times ranked

240

4063 citing authors

#	Article	IF	CITATIONS
1	Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. Clinical Infectious Diseases, 2013, 57, S51-S55.	2.9	161
2	Knowledge and Attitudes about Treatment for Hepatitis C Virus Infection and Barriers to Treatment among Current Injection Drug Users in Australia. Clinical Infectious Diseases, 2005, 40, S313-S320.	2.9	133
3	Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis. International Journal of Drug Policy, 2017, 44, 192-201.	1.6	109
4	Perceptions of discriminatory treatment by staff as predictors of drug treatment completion: Utility of a mixed methods approach. Drug and Alcohol Review, 2010, 29, 491-497.	1.1	108
5	The social production of hepatitis C risk among injecting drug users: a qualitative synthesis. Addiction, 2008, 103, 1593-1603.	1.7	103
6	Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 2013, 57, S62-S69.	2.9	97
7	Single index of multimorbidity did not predict multiple outcomes. Journal of Clinical Epidemiology, 2005, 58, 997-1005.	2.4	95
8	Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. Journal of Viral Hepatitis, 2010, 17, 839-844.	1.0	92
9	Needle sharing in regular sexual relationships: An examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug and Alcohol Dependence, 2010, 107, 182-187.	1.6	88
10	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. Liver International, 2019, 39, 20-30.	1.9	88
11	The Lived Experience of Hepatitis C and its Treatment Among Injecting Drug Users: Qualitative Synthesis. Qualitative Health Research, 2009, 19, 1321-1334.	1.0	85
12	Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?. PLoS ONE, 2018, 13, e0207226.	1.1	77
13	â€~Spoiled identity' in hepatitis C infection: The binary logic of despair. Critical Public Health, 2006, 16, 99-110.	1.4	76
14	Trust and people who inject drugs: The perspectives of clients and staff of Needle Syringe Programs. International Journal of Drug Policy, 2016, 27, 138-145.	1.6	76
15	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open, 2016, 4, E605-E614.	1.1	74
16	Some characteristics of early-onset injection drug users prior to and at the time of their first injection. Addiction, 2006, 101, 548-555.	1.7	72
17	Blood and bioidentity: ideas about self, boundaries and risk among blood donors and people living with Hepatitis C. Social Science and Medicine, 2004, 59, 1461-1471.	1.8	70
18	Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 2015, 26, 992-998.	1.6	65

#	Article	IF	CITATIONS
19	The gendered context of initiation to injecting drug use: evidence for women as active initiates. Drug and Alcohol Review, 2007, 26, 287-293.	1.1	63
20	Pleasure and drugs. International Journal of Drug Policy, 2008, 19, 349-352.	1.6	63
21	Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Drug and Alcohol Review, 2012, 31, 918-924.	1.1	63
22	Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study. Addiction, 2016, 111, 311-319.	1.7	63
23	Deficit models and divergent philosophies: Service providers' perspectives on barriers and incentives to drug treatment. Drugs: Education, Prevention and Policy, 2006, 13, 367-382.	0.8	58
24	Laws prohibiting peer distribution of injecting equipment in Australia: A critical analysis of their effects. International Journal of Drug Policy, 2015, 26, 1198-1206.	1.6	58
25	"We are people too― Consumer participation and the potential transformation of therapeutic relations within drug treatment. International Journal of Drug Policy, 2015, 26, 30-36.	1.6	57
26	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	1.6	57
27	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. International Journal of Drug Policy, 2017, 47, 51-60.	1.6	54
28	Equity of access to treatment, and barriers to treatment for illicit drug use in Australia. Addiction, 2007, 102, 958-969.	1.7	53
29	Barriers and facilitators for assessment and treatment of hepatitis <scp>C</scp> virus infection in the opioid substitution treatment setting: insights from the <scp>ETHOS</scp> study. Journal of Viral Hepatitis, 2014, 21, 560-567.	1.0	53
30	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. International Journal of Drug Policy, 2017, 47, 26-33.	1.6	53
31	The rush to risk when interrogating the relationship between methamphetamine use and sexual practice among gay and bisexual men. International Journal of Drug Policy, 2018, 55, 242-248.	1.6	51
32	Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study. The Lancet Gastroenterology and Hepatology, 2021, 6, 533-546.	3.7	48
33	Ethical challenges and responses in harm reduction research: promoting applied communitarian ethics. Drug and Alcohol Review, 2005, 24, 449-459.	1.1	46
34	Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice. Drugs: Education, Prevention and Policy, 2007, 14, 61-74.	0.8	45
35	Beyond cure: patient reported outcomes of hepatitis C treatment among people who inject drugs in Australia. Harm Reduction Journal, 2018, 15, 42.	1.3	45
36	Measuring Social Capital in the Prison Setting: Lessons Learned From the Inmate Social Capital Questionnaire. Journal of Correctional Health Care, 2018, 24, 407-417.	0.2	44

#	Article	IF	CITATIONS
37	Understanding facilitators and barriers of directâ€acting antiviral therapy for hepatitis C virus infection in prison. Journal of Viral Hepatitis, 2018, 25, 1526-1532.	1.0	44
38	Factors affecting progress of Australian and international students in a problem-based learning medical course. Medical Education, 2000, 34, 708-715.	1.1	43
39	How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. International Journal of Drug Policy, 2014, 25, 865-870.	1.6	43
40	Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 2015, 26, 999-1006.	1.6	43
41	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Clinical Infectious Diseases, 2021, 73, e69-e78.	2.9	43
42	Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug and Alcohol Dependence, 2011, 116, 52-56.	1.6	42
43	Perceived discrimination and injecting risk among people who inject drugs attending Needle and Syringe Programmes in Sydney, Australia. Drug and Alcohol Dependence, 2014, 144, 274-278.	1.6	42
44	Destabilising the †problem†of chemsex: Diversity in settings, relations and practices revealed in Australian gay and bisexual men's crystal methamphetamine use. International Journal of Drug Policy, 2020, 78, 102697.	1.6	42
45	Hepatitis C and injecting-related discrimination in New South Wales, Australia. Drugs: Education, Prevention and Policy, 2006, 13, 61-75.	0.8	41
46	Initiators: An Examination of Young Injecting Drug Users Who Initiate Others to Injecting. AIDS and Behavior, 2008, 12, 885-890.	1.4	40
47	Multiple stigmas, shame and historical trauma compound the experience of Aboriginal Australians living with hepatitis C. Health Sociology Review, 2016, 25, 18-32.	1.7	40
48	Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. International Journal of Drug Policy, 2019, 72, 1-10.	1.6	40
49	The Experience of Interferon-Based Treatments for Hepatitis C Infection. Qualitative Health Research, 2005, 15, 635-646.	1.0	39
50	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
51	Information exchange among injecting drug users: a role for an expanded peer education workforce. International Journal of Drug Policy, 2005, 16, 46-53.	1.6	38
52	Chronic Illness Experiences, Clinical Markers and Living with Hepatitis C. Journal of Health Psychology, 2007, 12, 330-340.	1.3	38
53	Public opinion on needle and syringe programmes: avoiding assumptions for policy and practice. Drug and Alcohol Review, 2007, 26, 355-361.	1.1	38
54	"l can't do this, it's too much― building social inclusion in cancer diagnosis and treatment experiences of Aboriginal people, their carers and health workers. International Journal of Public Health, 2014, 59, 373-379.	1.0	37

#	Article	IF	CITATIONS
55	Critical appraisal checklist for qualitative research studies. Indian Journal of Pediatrics, 2000, 67, 347-351.	0.3	35
56	Barriers to use of Needle and Syringe Programmes in a high drug use area of Sydney, New South Wales. International Journal of Drug Policy, 2005, 16, 308-315.	1.6	35
57	How can hepatitis C be prevented in the long term?. International Journal of Drug Policy, 2007, 18, 338-340.	1.6	35
58	Exploring the role of consumer participation in drug treatment. Drug and Alcohol Dependence, 2009, 105, 172-175.	1.6	33
59	Rethinking safety and fidelity: The role of love and intimacy in hepatitis C transmission and prevention. Health Sociology Review, 2012, 21, 272-286.	1.7	33
60	Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy, 2015, 26, 893-898.	1.6	33
61	â€~Naloxone works': The politics of knowledge in â€~evidence-based' drug policy. Health (United Kingdom 2017, 21, 278-294.) _{0.9}	33
62	Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Australian Health Review, 2008, 32, 570.	0.5	33
63	Indigenous Australian medical students' perceptions of their medical school training. Medical Education, 2009, 43, 1047-1055.	1.1	32
64	Diffracting addicting binaries: An analysis of personal accounts of alcohol and other drug â€~addiction'. Health (United Kingdom), 2017, 21, 519-537.	0.9	32
65	The politics of place(ment): Problematising the provision of hepatitis C treatment within opiate substitution clinics. Social Science and Medicine, 2012, 74, 245-253.	1.8	31
66	Health literacy in relation to cancer: addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services. Health and Social Care in the Community, 2013, 21, n/a-n/a.	0.7	31
67	Do women with complex alcohol and other drug use histories want womenâ€only residential treatment?. Addiction, 2018, 113, 989-997.	1.7	31
68	Making sense of â€~side effects': Counterpublic health in the era of direct-acting antivirals. International Journal of Drug Policy, 2019, 72, 77-83.	1.6	31
69	The role of social support in moderating the relationship between HIV centrality, internalised stigma and psychological distress for people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 850-857.	0.6	31
70	Comparison of needle and syringe programme attendees and non-attendees from a high drug-using area in Sydney, New South Wales. Drug and Alcohol Review, 2006, 25, 439-444.	1,1	30
71	Rethinking the relationship between sex work, mental health and stigma: a qualitative study of sex workers in Australia. Social Science and Medicine, 2021, 268, 113468.	1.8	30
72	Infection Control in the Context of Hepatitis C Disclosure: Implications for Education of Healthcare Professionals. Education for Health: Change in Learning and Practice, 2004, 17, 183-191.	0.1	30

#	Article	IF	Citations
73	Needle and syringe programmes in the local media: "needle anger―versus "effective education in the community― International Journal of Drug Policy, 2004, 15, 46-55.	1.6	29
74	Broadening discussions of "safe―in hepatitis C prevention: A close-up of swabbing in an analysis of video recordings of injecting practice. International Journal of Drug Policy, 2008, 19, 59-65.	1.6	29
75	†Not just Methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings. Addiction, 2014, 109, 452-459.	1.7	29
76	Evaluation of an online injecting drug use stigma intervention targeted at health providers in New South Wales, Australia. Health Psychology Open, 2017, 4, 205510291770718.	0.7	29
77	Practices of partnership: Negotiated safety among couples who inject drugs. Health (United Kingdom), 2018, 22, 3-19.	0.9	29
78	Complex vulnerabilities as barriers to treatment for illicit drug users with high prevalence mental health co-morbidities. Mental Health and Substance Use: Dual Diagnosis, 2008, 1, 84-95.	0.5	28
79	Resilient Coping. Journal of Health Psychology, 2008, 13, 17-27.	1.3	28
80	Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia. Drug and Alcohol Dependence, 2013, 133, 529-534.	1.6	26
81	The intimate relationship as a site of social protection: Partnerships between people who inject drugs. Social Science and Medicine, 2017, 180, 125-134.	1.8	26
82	Hepatitis C prevention education needs to be grounded in social relationships. Drugs: Education, Prevention and Policy, 2014, 21, 88-92.	0.8	25
83	New narratives, new selves: Complicating addiction in online alcohol and other drug resources. Addiction Research and Theory, 2015, 23, 499-509.	1.2	25
84	Responding to a national policy need: development of a stigma indicator for bloodborne viruses and sexually transmissible infections. Australian and New Zealand Journal of Public Health, 2018, 42, 513-515.	0.8	25
85	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	1.0	25
86	Stigmatising attitudes towards people who inject drugs, and people living with blood borne viruses or sexually transmissible infections in a representative sample of the Australian population. PLoS ONE, 2020, 15, e0232218.	1.1	25
87	Doing things together? Analysis of health education materials to inform hepatitis C prevention among couples. Addiction Research and Theory, 2011, 19, 352-361.	1.2	24
88	Staying Safe From Hepatitis C. Qualitative Health Research, 2012, 22, 31-42.	1.0	24
89	Evaluation of the Deadly Liver Mob program: insights for roll-out and scale-up of a pilot program to engage Aboriginal Australians in hepatitis C and sexual health education, screening, and care. Harm Reduction Journal, 2018, 15, 5.	1.3	24
90	At the intersection of marginalised identities: lesbian, gay, bisexual and transgender people's experiences of injecting drug use and hepatitis C seroconversion. Health and Social Care in the Community, 2013, 21, 402-410.	0.7	23

#	Article	IF	Citations
91	The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?. PLoS ONE, 2016, 11, e0162399.	1.1	23
92	Hepatitis Câ€related discrimination in healthcare. Medical Journal of Australia, 2002, 177, 233-234.	0.8	22
93	Is point of access to needles and syringes related to needle sharing? Comparing data collected from pharmacies and needle and syringe programs in southâ€east Sydney. Drug and Alcohol Review, 2010, 29, 364-370.	1.1	22
94	Normalisation of recreational drug use among young people: Evidence about accessibility, use and contact with other drug users. Health Sociology Review, 2010, 19, 164-175.	1.7	22
95	Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments. Ethnicity and Health, 2016, 21, 39-57.	1.5	22
96	Multidisciplinary Cross-National Studies: A Commentary on Issues of Collaboration, Methodology, Analysis, and Publication. Qualitative Health Research, 2003, 13, 924-932.	1.0	21
97	The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection. International Journal of Drug Policy, 2007, 18, 374-380.	1.6	21
98	Disclosing Hepatitis C Infection Within Everyday Contexts. Journal of Health Psychology, 2010, 15, 811-818.	1.3	21
99	<i><scp>A</scp>ddiction</i> journal is committed to publishing qualitative research. Addiction, 2013, 108, 447-449.	1.7	21
100	One size fits all? The discursive framing of cultural difference in health professional accounts of providing cancer care to Aboriginal people. Ethnicity and Health, 2013, 18, 433-447.	1.5	21
101	Acquiring hepatitis C in prison: the social organisation of injecting risk. Harm Reduction Journal, 2015, 12, 10.	1.3	21
102	Experiences of diagnosis, care and treatment among Aboriginal people living with hepatitis C. Australian and New Zealand Journal of Public Health, 2016, 40, S59-S64.	0.8	21
103	"Look, I'm fit, I'm positive and I'll be all right, thank you very much†Coping with hepatitis C treatment and unrealistic optimism. Psychology, Health and Medicine, 2008, 13, 360-366.	1.3	20
104	Discrimination by health care workers versus discrimination by others: Countervailing forces on HCV treatment intentions. Psychology, Health and Medicine, 2015, 20, 148-153.	1.3	20
105	Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs. International Journal of Drug Policy, 2019, 66, 87-93.	1.6	20
106	A diagnosis of hepatitis C - insights from a study on patients' experiences. Australian Family Physician, 2010, 39, 589-92.	0.5	20
107	Risk practices and other characteristics of injecting drug users who obtain injecting equipment from pharmacies and personal networks. International Journal of Drug Policy, 2006, 17, 418-424.	1.6	19
108	Cancer and Aboriginal people in Australia: A review of the literature. Critical Public Health, 2008, 18, 65-75.	1.4	19

#	Article	IF	CITATIONS
109	Rural General Practitioner Apprehension About Work Related Violence in Australia. Australian Journal of Rural Health, 2003, 11, 237-241.	0.7	18
110	The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 2015, 26, 1094-1102.	1.6	18
111	Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug and Alcohol Dependence, 2018, 183, 96-101.	1.6	18
112	Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot. International Journal of Drug Policy, 2022, 107, 103788.	1.6	18
113	Needle fictions: medical constructions of needle fixation and the injecting drug user. Addiction Research and Theory, 2004, 12, 67-76.	1.2	17
114	Prisons, hepatitis C and harm minimisation. Medical Journal of Australia, 2007, 186, 647-649.	0.8	17
115	Hepatitis C treatment in pharmacotherapy services: Increasing treatment uptake needs a critical view. Drug and Alcohol Review, 2009, 28, 436-440.	1.1	17
116	Assessing community support for harm reduction services: Comparing two measures. Drug and Alcohol Review, 2010, 29, 385-391.	1.1	17
117	"We get by with a little help from our friends― Small-scale informal and large-scale formal peer distribution networks of sterile injecting equipment in Australia. International Journal of Drug Policy, 2016, 34, 65-71.	1.6	17
118	"Don't think l'm going to leave you over it╠Accounts of changing hepatitis C status among couples who inject drugs. Drug and Alcohol Dependence, 2017, 173, 78-84.	1.6	17
119	â€~Affording' new approaches to couples who inject drugs: A novel fitpack design for hepatitis C prevention. International Journal of Drug Policy, 2017, 50, 19-35.	1.6	17
120	Predictors of health care workers' support for discriminatory treatment and care of people who inject drugs. Psychology, Health and Medicine, 2019, 24, 439-445.	1.3	17
121	Use of interventions to minimise perioperative allogeneic blood transfusion in Australia A survey by the International Study of Perioperative Transfusion (ISPOT) study group. Medical Journal of Australia, 2000, 172, 365-369.	0.8	16
122	"Fitness for duty― Social, organisational and structural influences on the design and conduct of candidate hepatitis C vaccine trials involving people who inject drugs. Vaccine, 2010, 28, 5228-5236.	1.7	16
123	Priorities and practices of risk reduction among gay and bisexual men in Australia who use crystal methamphetamine for sex. International Journal of Drug Policy, 2021, 93, 103163.	1.6	16
124	Stigma as understood by key informants: A social ecological approach to gay and bisexual men's use of crystal methamphetamine for sex. International Journal of Drug Policy, 2021, 94, 103229.	1.6	16
125	Hepatitis C, blood and models of the body: New directions for public health. Critical Public Health, 2004, 14, 377-389.	1.4	15
126	Evaluation of Consumer Participation Demonstration Projects in Five Australian Drug User Treatment Facilities: The Impact of Individual Versus Organizational Stability in Determining Project Progress. Substance Use and Misuse, 2011, 46, 969-979.	0.7	15

#	Article	IF	CITATIONS
127	â€ïl Wouldn't Call the Cops if I was Being Bashed to Death': Sex Work, Whore Stigma and the Criminal Legal System. International Journal for Crime, Justice and Social Democracy, 2021, 10, .	0.9	15
128	Structural competency in the post-prison period for people who inject drugs: A qualitative case study. International Journal of Drug Policy, 2021, 95, 103261.	1.6	15
129	Prediction of intern attendance at a seminar-based training programme: a behavioural intention model. Medical Education, 2000, 34, 512-518.	1.1	14
130	Examining structural violence in opioid pharmacotherapy treatment in Australia: Sweating the "small stuff―in a liberal paradise. International Journal of Drug Policy, 2013, 24, e11-e13.	1.6	14
131	The role of Aboriginal community attachment in promoting lifestyle changes after hepatitis C diagnosis. Health Psychology Open, 2015, 2, 205510291560158.	0.7	14
132	Salvaging a prison needle and syringe program trial in Australia requires leadership and respect for evidence. Medical Journal of Australia, 2015, 203, 319-320.	0.8	14
133	Contextualising the social capital of Australian Aboriginal and non-Aboriginal men in prison. Social Science and Medicine, 2016, 167, 29-36.	1.8	14
134	Beyond equipment distribution in Needle and Syringe Programmes: an exploratory analysis of blood-borne virus risk and other measures of client need. Harm Reduction Journal, 2016, 13, 18.	1.3	14
135	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. Critical Public Health, 2019, 29, 260-273.	1.4	14
136	A qualitative exploration of SMART Recovery meetings in Australia and the role of a digital platform to support routine outcome monitoring. Addictive Behaviors, 2020, 101, 106144.	1.7	14
137	"That was quick, simple, and easy― Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison. International Journal of Drug Policy, 2022, 99, 103456.	1.6	14
138	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy, 2022, 105, 103706.	1.6	14
139	Evaluation of an integrated care service facility for people living with hepatitis C in New Zealand. International Journal of Integrated Care, 2012, 12, e229.	0.1	13
140	Hepatitis C, love and intimacy: Beyond the â€~anomalous body'. Drugs: Education, Prevention and Policy, 2011, 18, 228-236.	0.8	12
141	Peer education for people who inject drugs in New South Wales: Advantages, unanticipated benefits and challenges. Drugs: Education, Prevention and Policy, 2013, 20, 304-311.	0.8	12
142	Unlocking dimensions of social capital in the prison setting. Health and Justice, 2016, 4, 9.	0.9	12
143	Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting. International Journal of Drug Policy, 2020, 77, 102693.	1.6	12
144	Online interventions to reduce stigma towards population groups affected by blood borne viruses in Australia. International Journal of Drug Policy, 2021, 96, 103292.	1.6	12

#	Article	IF	Citations
145	Under the watchful eye of 'a benevolent dictator' - general practitioner and patient experiences of hepatitis C treatment initiation and shared-care in general practice. Australian Family Physician, 2013, 42, 900-3.	0.5	12
146	Evaluation of an instrument to assess the needs of men diagnosed with prostate carcinoma. Cancer, 2003, 97, 993-1001.	2.0	11
147	Evaluation of a revised instrument to assess the needs of men diagnosed with prostate cancer. Supportive Care in Cancer, 2005, 13, 895-903.	1.0	11
148	Pretreatment preparation and management of interferon-based therapy for hepatitis C virus infection. Journal of Advanced Nursing, 2007, 59, 248-254.	1.5	11
149	Managing Mental Health Problems in Everyday Life: Drug Treatment Clients' Self-Care Strategies. International Journal of Mental Health and Addiction, 2008, 6, 421-431.	4.4	11
150	Authenticity and Diversity: Enhancing Australian Hepatitis C Prevention Messages. Contemporary Drug Problems, 2013, 40, 505-529.	0.7	11
151	Hepatitis C prevention and convenience: why do people who inject drugs in sexual partnerships â€run out' of sterile equipment?. Critical Public Health, 2016, 26, 294-306.	1.4	11
152	HIV stigma by association among Australian gay and bisexual men. Aids, 2020, 34, S53-S61.	1.0	11
153	Hepatitis C cure as a â€~gathering': Attending to the social and material relations of hepatitis C treatment. Sociology of Health and Illness, 2022, 44, 830-847.	1.1	11
154	Does anyone know where to get fits from around here?' Policy implications for the provision of sterile injecting equipment through pharmacies in Sydney, Australia. Drugs: Education, Prevention and Policy, 2010, 17, 72-83.	0.8	10
155	Using mindfulness to develop health education strategies for blood borne virus prevention in injecting drug use. Drugs: Education, Prevention and Policy, 2010, 17, 431-442.	0.8	10
156	â€~Makes you wanna do treatment': Benefits of a hepatitis C specialist clinic to clients in Christchurch, New Zealand. Health and Social Care in the Community, 2013, 21, 216-223.	0.7	10
157	"Doing the devil's work― Emotional labour and stigma in expanding Needle and Syringe Programs. Drugs: Education, Prevention and Policy, 2015, 22, 437-443.	0.8	10
158	â€I didn't want to let it go too far.' The decisions and experiences of people who inject drugs who received a liver disease assessment as part of a liver health promotion campaign: The LiveRLife study. International Journal of Drug Policy, 2017, 47, 153-160.	1.6	10
159	Identifying risk and protective factors, including culture and identity, for methamphetamine use in Aboriginal and Torres Strait Islander communities: Relevance of the †communities that care†model. Social Science and Medicine, 2020, 266, 113451.	1.8	10
160	Alcohol and other drug treatment experiences of hepatitis C-positive and negative clients: implications for hepatitis C treatment. Australian Health Review, 2009, 33, 100.	0.5	10
161	A gender lens is needed in hepatitis C elimination research. International Journal of Drug Policy, 2022, 103, 103654.	1.6	10
162	†You Sort of Switch Off': Exploring Mindlessness in Injecting Drug Users' Accounts of Blood. Journal of Health Psychology, 2005, 10, 137-145.	1.3	9

#	Article	IF	CITATIONS
163	Preventing transitions to injecting amongst young people: What is the role of Needle and Syringe Programmes?. International Journal of Drug Policy, 2010, 21, 160-164.	1.6	9
164	Depression, Anxiety, and Stress Among People With Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 2017, 11, 10-18.	1.4	9
165	Acceptability of Patient-Reported Outcome and Experience Measures for Hepatitis C Treatment Among People Who Use Drugs. Patient, 2019, 12, 259-265.	1.1	9
166	Knowledge and beliefs about hepatitis B virus infection and associated factors among Chinese migrants in Australia: The result of a quantitative study. Health and Social Care in the Community, 2022, 30, 918-925.	0.7	9
167	Health service utilization and experiences of stigma amongst people who inject drugs in Melbourne, Australia. Journal of Viral Hepatitis, 2021, 28, 1738-1743.	1.0	9
168	A piece of the jigsaw of primary care: health professional perceptions of an integrated care model of hepatitis C management in the community. Journal of Primary Health Care, 2014, 6, 129.	0.2	8
169	Listening to the consumer voice: developing multilingual cancer information resources for people affected by liver cancer. Health Expectations, 2017, 20, 171-182.	1.1	8
170	A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons. Harm Reduction Journal, 2018, 15, 39.	1.3	8
171	Positive effects of community attachment on internalised stigma and wellbeing among people who inject drugs. International Journal of Drug Policy, 2021, 97, 103323.	1.6	8
172	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study. JMIR Research Protocols, 2020, 9, e15113.	0.5	8
173	Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in SMART Recovery Mutual Support Groups: Stage 1 Mixed Methods Pilot Study. Journal of Medical Internet Research, 2021, 23, e25217.	2.1	8
174	NSPs and the media: a case study of balanced and accurate reporting?. Australian and New Zealand Journal of Public Health, 2005, 29, 489-490.	0.8	7
175	Social inclusion and hepatitis C: exploring new possibilities for prevention. Expert Review of Anti-Infective Therapy, 2011, 9, 397-404.	2.0	7
176	Structural constraints on the training of peer educators in hepatitis C prevention. Health Education Research, 2012, 27, 248-257.	1.0	7
177	Young people at risk of transitioning to injecting drug use in Sydney, Australia: social disadvantage and other correlates of higher levels of exposure to injecting. Health and Social Care in the Community, 2015, 23, 200-207.	0.7	7
178	Understanding decisions made about hepatitis C treatment by couples who inject drugs. Journal of Viral Hepatitis, 2016, 23, 89-95.	1.0	7
179	"l Had a Little Bit of a Bloke Meltdown… But the Next Day, I Was Up― Cancer Nursing, 2017, 40, E1-E8.	0.7	7
180	Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. International Journal of Drug Policy, 2021, 96, 103469.	1.6	7

#	Article	IF	CITATIONS
181	"It's a revolving door― Ego-depletion among prisoners with injecting drug use histories as a barrier to post-release success. International Journal of Drug Policy, 2022, 101, 103571.	1.6	7
182	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses, 2022, 14, 1555.	1.5	7
183	An 'Academic Detailing' Intervention To Decrease Exposure to HIV Infection among Health-care Workers. Journal of Health Psychology, 1996, 1, 455-468.	1.3	6
184	Representations of people with HIV and hepatitis C in editorials of medical journals: Discourses and interdiscursive relations. Communication and Medicine, 2006, 3, 15-25.	0.1	6
185	The role of social capital in facilitating hepatitis C treatment scaleâ€up within a treatmentâ€asâ€prevention trial in the male prison setting. Addiction, 2021, 116, 1162-1171.	1.7	6
186	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. Drug and Alcohol Dependence, 2022, 237, 109543.	1.6	6
187	Applied communitarian ethics for harm reduction: promoting a dialogue within the field. Drug and Alcohol Review, 2007, 26, 553-555.	1.1	5
188	Working with the "hierarchy in the Underworld†Insights for Communication Skills Training with Peer Educators. Contemporary Drug Problems, 2010, 37, 639-657.	0.7	5
189	Harm minimisation in Australian prisons â€" health protection still depends on where you serve your time. Medical Journal of Australia, 2012, 197, 382-382.	0.8	5
190	Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation. International Journal of Drug Policy, 2020, 86, 102964.	1.6	5
191	Expert stakeholder perspectives on the acceptability of treatmentâ€asâ€prevention in prison: a qualitative substudy of the †Surveillance and Treatment of Prisoners with Hepatitis C' project (SToPâ€C). Addiction, 2021, 116, 2761-2769.	1.7	5
192	The power of naming: A reply to McBride and Pates. Addiction Research and Theory, 2005, 13, 403-404.	1.2	4
193	Health worker attitudes toward peer workers in hepatitis C prevention. Psychology, Health and Medicine, 2012, 17, 659-666.	1.3	4
194	Response to Chandler et al., Substance, structure and stigma: Parents in the UK accounting for opioid substitution therapy during the antenatal and postnatal periods. International Journal of Drug Policy, 2013, 24, e87-e88.	1.6	4
195	What's the Cost of Finding the Right Fit? The Cost of Conducting NSP Business in a Range of Modalities. Contemporary Drug Problems, 2014, 41, 41-56.	0.7	4
196	A qualitative study trialling the acceptability of new hepatitis C prevention messages for people who inject drugs: symbiotic messages, pleasure and conditional interpretations. Harm Reduction Journal, 2015, 12, 5.	1.3	4
197	Harm reduction workers and the challenge of engaging couples who inject drugs in hepatitis C prevention. Drug and Alcohol Dependence, 2016, 168, 170-175.	1.6	4
198	<i>àẽlt's Fast, It's Quick, It Stops Me Being Sick'</i> : How to influence preparation of opioid tablets for injection. Drug and Alcohol Review, 2017, 36, 651-657.	1.1	4

#	Article	IF	CITATIONS
199	Enhancing engagement in hepatitis C care among people who inject drugs. Addiction, 2019, 114, 2104-2106.	1.7	4
200	â€Behind closed doors, no one sees, no one knows': hepatitis C, stigma and treatment-as-prevention in prison. Critical Public Health, 2020, 30, 130-140.	1.4	4
201	Australian health and medical workers' concerns around providing care to people living with hepatitis B. Health and Social Care in the Community, 2021, 29, e431-e439.	0.7	4
202	A Web-Based Therapeutic Program (We Can Do This) for Reducing Methamphetamine Use and Increasing Help-Seeking Among Aboriginal and Torres Strait Islander People: Protocol for a Randomized Wait-List Controlled Trial. JMIR Research Protocols, 2019, 8, e14084.	0.5	4
203	Violence and hepatitis C transmission in prisonâ€"A modified social ecological model. PLoS ONE, 2020, 15, e0243106.	1.1	4
204	A piece of the jigsaw of primary care: health professional perceptions of an integrated care model of hepatitis C management in the community. Journal of Primary Health Care, 2014, 6, 129-34.	0.2	4
205	Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project. Harm Reduction Journal, 2022, 19, 40.	1.3	4
206	†Even though you hate everything that's going on, you know they are safer at home': The role of Aboriginal and Torres Strait Islander families in methamphetamine use harm reduction and their own support needs. Drug and Alcohol Review, 0, , .	1.1	4
207	Understanding comorbidity? Australian service-user and provider perspectives on drug treatment and mental-health literacy. Drugs: Education, Prevention and Policy, 2008, 15, 518-531.	0.8	3
208	Sexual identity and its relationship to injecting in a sample of disadvantaged young drug users. Drug and Alcohol Review, 2016, 35, 218-222.	1,1	3
209	HCV knowledge among a sample of HCV positive Aboriginal Australians residing in New South Wales. Psychology, Health and Medicine, 2017, 22, 625-632.	1.3	3
210	Afterword. International Journal of Drug Policy, 2017, 49, 171-172.	1.6	3
211	Health protection and Australian prisons, 2018. Medical Journal of Australia, 2018, 209, 460.	0.8	3
212	â€~Fighting a losing battle': prisoners' perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures. Drugs: Education, Prevention and Policy, 2019, 26, 502-507.	0.8	3
213	Involving peers in research: the UNSW community reference panel. Harm Reduction Journal, 2019, 16, 52.	1.3	3
214	Lives of Substance: a mixed-method evaluation of a public information website on addiction experiences. Drugs: Education, Prevention and Policy, 2019, 26, 140-147.	0.8	3
215	C' the potential: needle and syringe programs as hepatitis C treatment sites. Drugs: Education, Prevention and Policy, 2020, 27, 92-94.	0.8	3
216	People in prison who inject drugs: who is trusted when it comes to information about hepatitis C?. Addiction Research and Theory, 2021, 29, 247-254.	1.2	3

#	Article	IF	Citations
217	Comparing Australian health worker and student attitudes and concerns about providing care to people living with hepatitis B. Health Promotion Journal of Australia, 2021, , .	0.6	3
218	Incorporating the message: Research dissemination with the injecting drug use field. International Journal of Health Promotion and Education, 2005, 43, 75-80.	0.4	2
219	Hepatitis C in an Australian Migrant Community: Knowledge of and Attitudes towards Transmission and Infection. Contemporary Drug Problems, 2010, 37, 659-683.	0.7	2
220	Mental health support workers' attitudes towards hepatitis C and injecting drug use: barriers to recovery?. Mental Health and Substance Use: Dual Diagnosis, 2014, 7, 217-229.	0.5	2
221	Commentary on Historical Trauma, Substance Use, and Indigenous People: Seven Generations From a "Big Event― Substance Use and Misuse, 2015, 50, 891-893.	0.7	2
222	Deconstructing injecting risk of hepatitis C virus transmission: Using strategic positioning to understand "higher risk―practices. Drugs: Education, Prevention and Policy, 2016, 23, 457-461.	0.8	2
223	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> Series. Addiction, 2017, 112, 1126-1127.	1.7	2
224	Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian â€~surveillance and treatment of prisoners with hepatitis C' project (SToP-C). Harm Reduction Journal, 2021, 18, 46.	1.3	2
225	"lt's time!†A qualitative exploration of the acceptability of hepatitis C notification systems to help eliminate hepatitis C. International Journal of Drug Policy, 2021, 97, 103280.	1.6	2
226	Knowledge and attitudes towards hepatitis C and injecting drug use among mental-health support workers of a community managed organisation. Australian Health Review, 2013, 37, 654.	0.5	2
227	The proof is in the toothpaste: police ordered exclusion as a result of research participation. Australian and New Zealand Journal of Public Health, 2010, 34, 533-534.	0.8	1
228	International Policies to Reduce Illicit Drug-Related Harm and Illicit Drug Use., 2013,, 735-743.		1
229	Exposure to injecting drug use and hepatitis C knowledge among an online sample of young people. Drugs: Education, Prevention and Policy, 2016, 23, 84-88.	0.8	1
230	Young people at risk of transitioning to injecting: what do they know about where to get sterile needles?. Vulnerable Children and Youth Studies, 2017, 12, 138-146.	0.5	1
231	Overdoselifesavers.org: a mixed-method evaluation of a public information website on experiences of overdose and using take-home naloxone to save lives. Drugs: Education, Prevention and Policy, 0, , 1-11.	0.8	1
232	Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs. International Journal of Drug Policy, 2015, 26, 1039-1040.	1.6	0
233	Building on feminist achievements to enhance choice for women seeking treatment. Addiction, 2018, 113, 1001-1002.	1.7	0
234	Commentary on the harm reduction reference group of justice health and forensic mental health network and corrective services NSW, Australia. International Journal of Prisoner Health, 2021, ahead-of-print, .	0.5	0